Novel flufenamic acid analogues as inhibitors of androgen receptor mediated transcription

ACS Chemical Biology

Volumn 4, Issue 10, 2009, Pages 834-843

  Féau, Clémentine ^a   Arnold, Leggy A ^a   Kosinski, Aaron ^a   Zhu, Fangyi ^a   Connelly, Michele ^a   Guy, R Kiplin ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; FLUFENAMIC ACID; FLUFENAMIC ACID DERIVATIVE; HEAT SHOCK PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE DISEASE; STRUCTURE ACTIVITY RELATION; TRANSCRIPTION INITIATION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; CELL LINE, TUMOR; FLUFENAMIC ACID; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; STRUCTURE-ACTIVITY RELATIONSHIP; TACROLIMUS BINDING PROTEINS; TRANSCRIPTIONAL ACTIVATION;

EID: 70350153884     PISSN: 15548929     EISSN: None     Source Type: Journal    
DOI: 10.1021/cb900143a     Document Type: Article

References (37)

1. Chang, C. (2002) Androgens and Androgen Receptor: Mechanisms, Functions, and Clinical Applications, Kluwer Academic Publishers, Norwell.
2. Gelmann, E. P. (2002) Molecular biology of the androgen receptor, J. Clin. Oncol. 20, 3001-3015.
3. Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schutz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., and Evans, R. M. (1995) The nuclear receptor superfamily: the second decade, Cell 83, 835-839. (Pubitemid 126663112)
4. Kemppainen, J. A., Lane, M. V., Sar, M., and Wilson, E. M. (1992) Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones, J. Biol. Chem. 267, 968-974.
5. Amler, L. C., Agus, D. B., LeDuc, C., Sapinoso, M. L., Fox, W. D., Kern, S., Lee, D., Wang, V., Leysens, M., Higgins, B., Martin, J., Gerald, W., Dracopoli, N., Cordon-Cardo, C., Scher, H. I., and Hampton, G. M. (2000) Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1, Cancer Res. 60, 6134-6141. (Pubitemid 30839646)
6. DePrimo, S. E., Diehn, M., Nelson, J. B., Reiter, R. E., Matese, J., Fero, M., Tibshirani, R., Brown, P. O., Brooks, J. D. (2002) Transcriptional programs activated by exposure of human prostate cancer cells to androgen, Genome Biol. 3, RESEARCH0032.
7. Nantermet, P. V., Xu, J., Yu, Y., Hodor, P., Holder, D., Adamski, S., Gentile, M. A., Kimmel, D. B., Harada, S., Gerhold, D., Freedman, L. P., and Ray, W. J. (2004) Identification of genetic pathways activated by the androgen receptor during the induction of proliferation in the ventral prostate gland, J. Biol. Chem. 279, 1310-1322. (Pubitemid 38082656)
8. Nelson, P. S., Clegg, N., Arnold, H., Ferguson, C., Bonham, M., White, J., Hood, L., and Lin, B. (2002) The program of androgen-responsive genes in neoplastic prostate epithelium, Proc. Natl. Acad. Sci. U.S.A. 99, 11890-11895. (Pubitemid 34994494)
9. McKenna, N. J., and O'Malley, B. W. (2002) Minireview: nuclear receptor coactivators - an update, Endocrinology 143, 2461-2465.
10. McKenna, N. J., and O'Malley, B. W. (2002) Combinatorial control of gene expression by nuclear receptors and coregulators, Cell 108, 465-474. (Pubitemid 34260872)
11. Berrevoets, C. A., Doesburg, P., Steketee, K., Trapman, J., and Brinkmann, A. O. (1998) Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the aminoterminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor2), Mol. Endocrinol. 12, 1172-1183. (Pubitemid 30659044)
12. Burd, C. J., Morey, L. M., and Knudsen, K. E. (2006) Androgen receptor corepressors and prostate cancer, Endocr.-Relat. Cancer 13, 979-994. (Pubitemid 46212560)
13. Estebanez-Perpina, E., Moore, J. M., Mar, E., Delgado-Rodrigues, E., Nguyen, P., Baxter, J. D., Buehrer, B. M., Webb, P., Fletterick, R. J., and Guy, R. K. (2005) The molecular mechanisms of coactivator utilization in ligand-dependent transactivation by the androgen receptor, J. Biol. Chem. 280, 8060-8068. (Pubitemid 40349704)
14. Warnmark, A., Treuter, E., Wright, A. P., and Gustafsson, J. A. (2003) Activation functions 1 and 2 of nuclear receptors: molecular strategies for transcriptional activation, Mol. Endocrinol. 17, 1901-1909. (Pubitemid 37287610)
15. Estebanez-Perpina, E., Arnold, L. A., Nguyen, P., Rodrigues, E. D., Mar, E., Bateman, R., Pallai, P., Shokat, K. M., Baxter, J. D., Guy, R. K., Webb, P., and Fletterick, R. J. (2007) A surface on the androgen receptor that allosterically regulates coactivator binding, Proc. Natl. Acad. Sci. U.S.A. 104, 16074-16079. (Pubitemid 350099366)
16. Klotz, L., and Schellhammer, P. (2005) Combined androgen blockade: the case for bicalutamide, Clin. Prostate Cancer 3, 215-219. (Pubitemid 40770199)
17. Marques, R. B., Erkens-Schulze, S., de Ridder, C. M., Hermans, K. G., Waltering, K., Visakorpi, T., Trapman, J., Romijn, J. C., and van Weerden, W. M. (2005) Androgen receptor modifications in prostate cancer cells upon long-term androgen ablation and antiandrogen treatment, Int. J. Cancer 117, 221-229. (Pubitemid 41377441)
18. Schellhammer, P. (1999) An update on bicalutamide in the treatment of prostate cancer, Expert Opin. Invest. Drugs 8, 849-860. (Pubitemid 29253497)
19. Gao, W., and Dalton, J. T. (2007) Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs), Drug Discovery Today 12, 241-248. (Pubitemid 46304320)
20. Narayanan, R., Mohler, M. L., Bohl, C. E., Miller, D. D., and Dalton, J. T. (2008) Selective androgen receptor modulators in preclinical and clinical development, Nucl. Recept. Signaling 6, e010.
21. Scher, H. I., and Sawyers, C. L. (2005) Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis, J. Clin. Oncol. 23, 8253-8261.
22. Buchanan, G., Yang, M., Harris, J. M., Nahm, H. S., Han, G., Moore, N., Bentel, J. M., Matusik, R. J., Horsfall, D. J., Marshall, V. R., Greenberg, N. M., and Tilley, W. D. (2001) Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function, Mol. Endocrinol. 15, 46-56. (Pubitemid 32156040)
23. Gottlieb, B., Beitel, L. K., Wu, J. H., and Trifiro, M. (2004) The androgen receptor gene mutations database (ARDB): 2004 update, Hum. Mutat. 23, 527-533. (Pubitemid 38720602)
24. Jung, F., Selvaraj, S., and Gargus, J. J. (1992) Blockers of platelet-derived growth factor-activated nonselective cation channel inhibit cell proliferation, Am. J. Physiol. 262, C1464-1470.
25. Zhu, W., Smith, A., and Young, C. Y. (1999) A nonsteroidal anti-inflammatory drug, flufenamic acid, inhibits the expression of the androgen receptor in LNCaP cells, Endocrinology 140, 5451-5454. (Pubitemid 30687160)
26. Bauman, D. R., Rudnick, S. I., Szewczuk, L. M., Jin, Y., Gopishetty, S., and Penning, T. M. (2005) Development of nonsteroidal anti-inflammatory drug analogs and steroid carboxylates selective for human aldo-keto reductase isoforms: potential antineoplastic agents that work independently of cyclooxygenase isozymes, Mol. Pharmacol. 67, 60-68. (Pubitemid 40069966)
27. Steckelbroeck, S., Jin, Y., Gopishetty, S., Oyesanmi, B., and Penning, T. M. (2004) Human cytosolic 3α-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3β-hydroxysteroid dehydrogenase activity: implications for steroid hormone metabolism and action, J. Biol. Chem. 279, 10784-10795. (Pubitemid 38379543)
28. Féau, C., Arnold, L. A., Kosinski, A., and Guy, R. K. (2009) A high-throughput ligand competition binding assay for the androgen receptor and other nuclear receptors, J. Biomol. Screening 14, 43-48.
29. Bisson, W. H., Cheltsov, A. V., Bruey-Sedano, N., Lin, B., Chen, J., Goldberger, N., May, L. T., Christopoulos, A., Dalton, J. T., Sexton, P. M., Zhang, X. K., and Abagyan, R. (2007) Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs, Proc. Natl. Acad. Sci. U.S.A. 104, 11927-11932. (Pubitemid 47185607)
30. Hansch, C., and Fujita, T. (1964) ρ-σ-π Analysis. A method for the correlation of biological activity and chemical structure, J. Am. Chem. Soc. 86, 1616-1626.
31. Arnold, L. A., Estebanez-Perpina, E., Togashi, M., Shelat, A., Ocasio, C. A., McReynolds, A. C., Nguyen, P., Baxter, J. D., Fletterick, R. J., Webb, P., and Guy, R. K. (2006) A high-throughput screening method to identify small molecule inhibitors of thyroid hormone receptor coactivator binding, Sci. STKE 2006, pl3.
32. Teichert, A., Arnold, L. A., Otieno, S., Oda, Y., Augustinaite, I., Geistlinger, T. R., Kriwacki, R. W., Guy, R. K., and Bikle, D. D. (2009) Quantification of the vitamin D receptor-coregulator interaction, Biochemistry 48, 1454-1461.
33. Wilson, V. S., Bobseine, K., Lambright, C. R., and Gray, L. E., Jr. (2002) A novel cell line, MDA-kb2, that stably expresses an androgen- and glucocorticoid-responsive reporter for the detection of hormone receptor agonists and antagonists, Toxicol. Sci. 66, 69-81.
34. Balimane, P. V., Han, Y. H., and Chong, S. (2006) Current industrial practices of assessing permeability and P-glycoprotein interaction, AAPS J. 8, E1-13.
35. Yu, S., Konstantin, T., Zhu, Z., Graham, T. (2005) Automation of a double-Sink PAMPA permeability assay on the Biomek→FX Laboratory Automation Workstation, Pharm. Discovery.
36. Febbo, P. G., Lowenberg, M., Thorner, A. R., Brown, M., Loda, M., and Golub, T. R. (2005) Androgen mediated regulation and functional implications of fkbp51 expression in prostate cancer, J. Urol. 173, 1772-1777. (Pubitemid 40524830)
37. Periyasamy, S., Warrier, M., Tillekeratne, M. P., Shou, W., and Sanchez, E. R. (2007) The immunophilin ligands cyclosporin A and FK506 suppress prostate cancer cell growth by androgen receptor-dependent and -independent mechanisms, Endocrinology 148, 4716-4726. (Pubitemid 47481542)